Introduction:
Cambrex plans to construct new stability storage facility to the pharmaceutical, medical device and life sciences industries across Europe.
Features:
The new cGMP facility laid with 20,000 square feet will expand the capacity for environmentally-controlled stability storage services to the pharmaceutical, medical device and life sciences industries across Europe.
The new state-of-the-art temperature-controlled and monitored storage facility offers 35,000 temperature-controlled storage areas for all major ICH climate zones, including long-term, medium and accelerated stability tests, including 2 – 8°C, 25°C / 60 percent RH and 40°C / 75 percent RH.
This expansion enables easy accessible capacity in continental Europe and the flexibility to respond quickly and efficiently to changing customer demands and serve pharmaceutical companies across Europe.
This expansion complements first quarter scientific's existing footprint in Waterford, Ireland and aligns with Cambrex's to expand its portfolio of speciality drug development and manufacturing solutions in North America and Europe.
Specifications:
Name Cambrex
Type New Construction
